{"entity":{"id":"clinical-research-malaysia","kind":"institution","name":"Clinical Research Malaysia","aka":["CRM"],"tldr":"A research management organisation set up by Malaysia's Ministry of Health in 2012 to bring industry clinical trials to Malaysian hospitals and support the investigators who run them.","summary":"Clinical Research Malaysia was established by the Ministry of Health in 2012 (company number 1006282-X) and describes itself as a research management organisation offering end-to-end support for clinical research, including feasibility studies and study coordinators. Its home page reports that it and AstraZeneca won the British Malaysian Chamber of Commerce's UK-Malaysia Partnership of the Year award in 2024 under a memorandum of understanding that included moving a clinical research management team to Malaysia and starting a first-in-human study, and that Roche chose Sarawak General Hospital as a site for a global first-in-human trial. It lists an office at KL Gateway, Jalan Kerinchi, Kuala Lumpur, and a new office in Penang.\n\nOf the trials in OnCo's records, 171 list a site in Malaysia (ClinicalTrials.gov participation data, counted on 4 November 2026); AstraZeneca and Merck Sharp & Dohme lead the most. The coordinates are a Kuala Lumpur centroid.","asOf":"2026-11-04","links":[{"label":"Clinical Research Malaysia","url":"https://clinicalresearch.my/"},{"label":"ClinicalTrials.gov: cancer studies with sites in Malaysia","url":"https://clinicaltrials.gov/search?country=Malaysia&cond=Cancer"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ministry-of-health-malaysia","npra-malaysia","institut-kanser-negara","ummc-kuala-lumpur"],"pathways":[],"terms":[],"trials":["nct07050043","flaura","keynote-966"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kuala Lumpur","country":"MY","lat":3.139,"lng":101.687,"institutionType":"government","website":"https://clinicalresearch.my/","programs":["Feasibility and site selection for sponsored trials","Study coordinator services","First-in-human trial support"]},"route":"/institutions/clinical-research-malaysia/","neighbours":{"institution":[{"id":"institut-kanser-negara","kind":"institution","name":"Institut Kanser Negara (National Cancer Institute, Malaysia)","route":"/institutions/institut-kanser-negara/"},{"id":"ministry-of-health-malaysia","kind":"institution","name":"Ministry of Health Malaysia","route":"/institutions/ministry-of-health-malaysia/"},{"id":"npra-malaysia","kind":"institution","name":"National Pharmaceutical Regulatory Agency (NPRA), Malaysia","route":"/institutions/npra-malaysia/"},{"id":"ummc-kuala-lumpur","kind":"institution","name":"University of Malaya Medical Centre","route":"/institutions/ummc-kuala-lumpur/"}],"trial":[{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/"},{"id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/"},{"id":"nct07050043","kind":"trial","name":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","route":"/trials/nct07050043/"}]}}